Wrap Text
Announcement of the annual general meeting poll results
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
26 July 2017
ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS
Mediclinic announces that at its Annual General Meeting (“AGM”) held on 25 July 2017, all
resolutions set out in the notice of the AGM were passed by the requisite majority of votes by
shareholders by way of poll. The results of the poll for each resolution were as follows:
TOTAL % OF VOTES % VOTES % VOTES
SHARES ISSUED FOR AGAINST WITHHELD
VOTED SHARE
CAPITAL
VOTED
ORDINARY
RESOLUTIONS
1. To receive the 643,346,097 87.26% 642,608,938 99.99% 211 0.01% 736,948
Company’s financial
statements and the
reports by the Directors
and auditors
2. To approve the Directors’ 643,346,097 87.26% 618,212,690 96.25% 24,075,900 3.75% 1,057,507
Remuneration Report
3. To approve the amended 643,346,097 87.26% 614,711,926 95.95% 25,915,697 4.05% 2,718,474
Directors’ Remuneration
Policy
4. To declare a final 643,346,097 87.26% 642,966,257 99.99% 211 0.01% 379,629
dividend of 4.70 pence
per ordinary share
5. To elect Jurgens 643,346,097 87.26% 640,899,142 99.68% 2,060,463 0.32% 386,492
Myburgh as a Director
6. To re-elect Danie 643,346,097 87.26% 642,864,882 99.99% 94,723 0.01% 386,492
Meintjes as a Director
7. To re-elect Dr Edwin 643,346,097 87.26% 625,998,995 97.38% 16,833,567 2.62% 513,535
Hertzog as a Director
8. To re-elect Jannie 643,346,097 87.26% 612,105,167 95.26% 30,444,213 4.74% 796,717
Durand as a Director
9. To re-elect Alan Grieve 643,346,097 87.26% 640,694,983 99.93% 445,220 0.07% 2,205,894
as a Director
10. To re-elect Seamus 643,346,097 87.26% 641,082,006 99.99% 46,572 0.01% 2,217,519
Keating as a Director
11. To re-elect Prof Dr 643,346,097 87.26% 641,083,644 99.99% 44,934 0.01% 2,217,519
Robert Leu as a Director
12. To re-elect Nandi 643,346,097 87.26% 642,901,226 99.99% 49,254 0.01% 395,617
Mandela as a Director
13. To re-elect Trevor 643,346,097 87.26% 632,937,299 98.72% 8,191,279 1.28% 2,217,519
Petersen as a Director
14. To re-elect Desmond 643,346,097 87.26% 639,878,832 99.87% 836,521 0.13% 2,630,744
Smith as a Director
15. To re-appoint 643,346,097 87.26% 642,446,940 99.99% 3,656 0.01% 895,501
PricewaterhouseCoopers
LLP as auditors of the
Company
16. To authorise the Audit 643,346,097 87.26% 642,417,589 99.98% 120,859 0.02% 807,649
and Risk Committee to
determine the
remuneration of the
auditors
17. To authorise the 643,346,097 87.26% 566,825,468 89.04% 69,771,641 10.96% 6,748,988
Directors to make
political donations
18. To authorise the 643,346,097 87.26% 527,047,324 82.04% 115,391,424 17.96% 907,349
Directors to allot ordinary
shares
SPECIAL
RESOLUTIONS
19. To authorise the 643,346,097 87.26% 583,771,316 91.13% 56,840,187 8.87% 2,734,594
Directors to dis-apply the
statutory pre-emption
rights
20. To authorise the 643,346,097 87.26% 591,889,385 93.19% 43,253,058 6.81% 8,203,654
Directors to dis-apply
pre-emption rights for
purposes of acquisitions
or capital investments
21. To authorise the 643,346,097 87.26% 641,126,245 99.99% 1,314 0.01% 2,218,538
amendment to the
Articles of Association
22. To approve the reduction 643,346,097 87.26% 617,065,427 96.43% 22,854,064 3.57% 3,426,606
in minimum notice period
for general meetings
(other than annual
general meetings)
VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDER ON
ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS
ORDINARY TOTAL % OF VOTES % VOTES % VOTED
RESOLUTIONS SHARES ISSUED FOR AGAINST WITHHELD
VOTED SHARE
CAPITAL
VOTED
9. To re-elect Alan Grieve 571,230,713 77.48% 568,579,599 99.92% 445,220 0.08% 2,205,894
as a Director
10. To re-elect Seamus 571,230,713 77.48% 568,966,622 99.99% 46,572 0.01% 2,217,519
Keating as a Director
11. To re-elect Prof Dr 571,230,713 77.48% 568,968,260 99.99% 44,934 0.01% 2,217,519
Robert Leu as a Director
12. To re-elect Nandi 571,230,713 77.48% 570,785,842 99.99% 49,254 0.01% 395,617
Mandela as a Director
13. To re-elect Trevor 571,230,713 77.48% 560,821,915 98.56% 8,191,279 1.44% 2,217,519
Petersen as a Director
14. To re-elect Desmond 571,230,713 77.48% 567,763,448 99.85% 836,521 0.15% 2,630,744
Smith as a Director
Notes:
1. Any proxy appointments giving discretion to the Chairman of the Meeting have been included
in the "For" total.
2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For"
or "Against" a resolution.
3. The Company's total ordinary shares in issue (total voting rights) as at 25 July 2017 was
737 243 810 ordinary shares of 10 pence each. Ordinary shareholders are entitled to one
vote per ordinary share held.
4. As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial
Conduct Authority's Listing Rules, each resolution to elect an independent non-executive
director (resolutions 9 to 14) have under Listing Rule 9.2.2E been approved by a majority of
the votes cast by:
(a) the shareholders of the Company as a whole; and
(b) the independent shareholders of the Company, that is, all the shareholders entitled to vote
on each resolution, excluding the controlling shareholder.
In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the
meeting has been submitted to the National Storage Mechanism and will shortly be available for
inspection at http://www.morningstar.co.uk/uk/NSM.
The complete poll results and details of proxy votes lodged before the AGM will be available shortly
on the Company’s website at www.mediclinic.com.
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa
(South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to
enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary
healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE
listed and UK-based private healthcare group.
Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals
and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient
beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with
more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with
more than 700 inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group
plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International
Limited was completed. Mediclinic International Limited was a South African based international
private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange,
since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates
(mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic
International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE
in South Africa and the NSX in Namibia.
For further information, please contact:
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 26/07/2017 08:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
